TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Chongqing Peg-Bio Biopharm Co., Ltd.
Roswell Park Cancer Institute
National Institutes of Health Clinical Center (CC)
Apollo Therapeutics Ltd
Washington University School of Medicine
First Affiliated Hospital of Zhejiang University
Memorial Sloan Kettering Cancer Center